Toronto, November 30, 2018 – to the Company’s news release dated May 31, 2018, regarding an intention to assign 3D Signatures Inc. (TSX-V:DXD) (the “Company” or “3DS“) announces that further

and Insolvency Act (the “BIA”) and the layoff of its employees and contractors, the Company’s current Board of Directors and executive management team do not intend to file for bankruptcy. The Company plans to re-hire laid off technical staff as business need arises. The Company continues to seek and negotiate further funding in the form of equity, convertible itself into bankruptcy under the Bankruptcy debt and debt to continue its operational programs.

Due to the resignation of several former directors, announced September 17, 2018, the current Board of Directors do not satisfy the independence requirements of the Company’s Board of Directors and Audit Committee with respect to TSX Venture Exchange Policy.

Appointment of additional Directors to fulfill the independence requirement of the board and audit committee is expected to occur at the Company’s upcoming annual general meeting planned to be held during the fourth week of February 2019.

The Company is currently in discussions with a number of potential candidates.

The Company’s securities will be reinstated for trading at the opening, Monday, December 3, 2018.

About 3DS

3DS (TSX-V:DXD) is a personalized medicine company with a proprietary software platform, TeloViewTM, that is designed to predict the course of certain diseases and to tailor treatment options for the individual patient. The technology is based on the three-dimensional analysis of telomeres, the protective caps at the ends of chromosomes. 3DS’ TeloViewTMsoftware platform measures the organization of the genome and its correspondence to; the stage of a given disease, the rate of progression of the disease, how different diseases will respond to various therapies, and a drug’s efficacy and toxicity. 3DS’ proprietary software is designed to go beyond identifying whether a patient suffers from a specific disease or condition. Instead, the TeloViewTM platform is designed to inform clinicians and patients with respect to how to personalize treatment and best manage an individual’s disease based on their unique TeloViewTM score. As healthcare moves increasingly toward better informed, patient-centric approaches, the Company intends for the TeloViewTM platform to deliver personalized medicine that allows for better treatments, leading to better outcomes.

The TeloViewTM platform is supported by 25 clinical studies involving more than 3,000 patients and 20 different cancers, plus Alzheimer’s disease. 3DS benefits from twenty years of research, $25M of non-dilutive investment into its platform and more than 130 supporting publications and holds a portfolio of patents related to three-dimensional telomere analysis for proliferative diseases, including (but not limited to) hematological disorders such as Hodgkin’s lymphoma, multiple myeloma, and chronic myeloid leukemia. 3DS’ intellectual property portfolio also covers prostate cancer, breast cancer, lung cancer, melanoma, colorectal cancer, and Alzheimer disease.

For more information, visit the Company’s website at: http://www.3dsignatures.com.

416-673-8487

info@3dsignatures.com

MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto ON, M5G 1L7

www.3dsignatures.com

page1image1548290864page1image1548291120page1image1548291376

For further information, please contact:

page1image1548295248

Hugh Rogers

page1image1548296880

Interim Chairman

TSX.V: DXD

page2image1549731936page2image1549724064

MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto ON, M5G 1L7

www.3dsignatures.comTSX.V: DXD

TSX Venture Exchange Disclaimer

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “intends”, “will”, or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward- looking statements regarding access to funding, collaboration and commercial opportunities, the Company’s assessment of current and future clinical programs, and efficacy and success of the TeloViewTM platform are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.